What is it about?
Efficacy of nivolumab for Asian patients was identical with global population and immune related adverse events, especially skin toxicities , related to its efficacy.
Featured Image
Read the Original
This page is a summary of: Two‐year follow‐up of a randomized phase
III
clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (
Che..., Head & Neck, June 2020, Wiley,
DOI: 10.1002/hed.26331.
You can read the full text:
Contributors
The following have contributed to this page
